Evidence map›Paper›PMID 37920821›Full record

ArticleIn silico pharmacology2023

Repurposing of clinically proven bioactive compounds for targeted treatment of Alzheimer's disease using molecular docking approach.

Thasma Loganath Babu Vasanth Kanth, Archi Raha, R M Vijay Murali, Natesan Yuvatha, Kasinathan Kumaran, Rangasamy Kirubakaran, K N ArulJothi

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In silico pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Thasma Loganath Babu Vasanth Kanth *Department of Genetic Engineering, Faculty of Engineering and Technology, SRM Institute of Science and Technology, SRM Nagar, Potheri, 603203 Chengalpattu Dt, Tamil Nadu India.
Archi Raha *Department of Genetic Engineering, Faculty of Engineering and Technology, SRM Institute of Science and Technology, SRM Nagar, Potheri, 603203 Chengalpattu Dt, Tamil Nadu India.
R M Vijay MuraliDepartment of Genetic Engineering, Faculty of Engineering and Technology, SRM Institute of Science and Technology, SRM Nagar, Potheri, 603203 Chengalpattu Dt, Tamil Nadu India.
Natesan YuvathaDepartment of Genetic Engineering, Faculty of Engineering and Technology, SRM Institute of Science and Technology, SRM Nagar, Potheri, 603203 Chengalpattu Dt, Tamil Nadu India.
Kasinathan KumaranDepartment of Genetic Engineering, Faculty of Engineering and Technology, SRM Institute of Science and Technology, SRM Nagar, Potheri, 603203 Chengalpattu Dt, Tamil Nadu India.
Rangasamy KirubakaranDepartment of Biotechnology, Vinayaka Mission's Kirupananda Variyar Engineering College, Vinayaka Mission's Research Foundation, Salem, Tamil Nadu India.
K N ArulJothiDepartment of Genetic Engineering, Faculty of Engineering and Technology, SRM Institute of Science and Technology, SRM Nagar, Potheri, 603203 Chengalpattu Dt, Tamil Nadu India.
SRM Institute of Science and Technology · INVinayaka Missions University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases like Alzheimer's have become a growing concern as it is difficult to cure. Tau protein is found to be playing a major role in Alzheimer's disease, and the majority of drugs that are currently on the market are not only prohibitively expensive but also come packaged with side effects that the body cannot tolerate. Repurposing existing compounds is a successful and optimistic strategy that offers reduced risk and increased possibility. We aim to retrieve the existing drugs and analyze them using

Indexed as

ADMET AnalysisBlood brain barrierFlavonoidsMolecular DockingNeurodegenerative DiseasesTau Protein

Identifiers

PMID37920821
PMCPMC10618149
OpenAlexW4388041425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.